Physician profile
Robert A Shaw
NPI 1811082803
$1,770.86
in general payments reported to CMS, 2019-2025
21 companies · none reported in 2025
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,771.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Amgen INC. | $217.03 | 2019 | |
| Ucb, INC. | $187.64 | 2019 | |
| Janssen Biotech, INC. | $164.03 | 2019 | |
| Novartis Pharmaceuticals Corporation | $123.41 | 2019 | |
| Abbvie INC. | $118.98 | 2019 | |
| E.R. Squibb & Sons, L.L.C. | $113.37 | 2019 | |
| Celgene Corporation | $96.39 | 2019 | |
| Mallinckrodt Enterprises LLC | $91.37 | 2019 | |
| Pfizer INC. | $86.67 | 2019 | |
| Hikma Pharmaceuticals USA | $79.06 | 2019 | |
| Horizon Therapeutics Plc | $68.16 | 2019 | |
| Glaxosmithkline, LLC. | $62.34 | 2019 | |
| Radius Health, INC. | $59.93 | 2019 | |
| Regeneron Healthcare Solutions, INC. | $58.68 | 2019 | |
| Genentech USA, INC. | $55.38 | 2019 |
Show all 21 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Antares Pharma, INC. | $38.40 | 2019 | |
| Merck Sharp & Dohme LLC | $37.64 | 2019 | |
| Zyla Life Sciences, INC. | $36.54 | 2019 | |
| Lilly USA, LLC | $28.45 | 2019 | |
| Pacira Therapeutics, INC. | $28.28 | 2019 | |
| Sanofi-Aventis U.S. LLC | $19.11 | 2019 |
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Robert Shaw listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.